Good afternoon and welcome to Markets Desk.
Iran is claiming four tankers were struck by mines in the Strait of Hormuz, a flashpoint development that is already rattling energy markets. Combined with renewed Houthi activity and reports that Washington is weighing fresh military options following the midterms, the risk premium on crude is climbing fast and shipping lanes through the strait remain under close watch.
Shifting to credit markets, Lennar Corporation has moved aggressively to shore up its balance sheet, amending its revolving credit facility to three point seven nine five billion dollars and expanding its term loan to one point seven five billion. For the homebuilder, this signals a clear intent to stay liquid and acquisitive heading into what could be a turbulent rate environment through the remainder of two thousand twenty six.
And in pharma, Novartis finds itself in a familiar but uncomfortable position. The company has navigated one patent cliff but disappointing clinical trial data is casting a shadow over its next generation of blockbuster candidates. Building a durable pipeline after losing exclusivity on core drugs is the defining challenge for large-cap biopharma right now, and Novartis is squarely in that spotlight.
That's the tape. Markets Desk, signing off the floor.
